Bayer Hlthcare patent expiration

1. Adempas patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6743798 BAYER HLTHCARE Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
Jul, 2019

(5 years ago)

US7173037 BAYER HLTHCARE Carbamate-substituted pyrazolopyridines
Dec, 2026

(2 years from now)

US11203593 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
Feb, 2034

(9 years from now)

US10662188 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Feb, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 08, 2018
Orphan Drug Exclusivity(ODE-53) Oct 08, 2020
Orphan Drug Exclusivity(ODE) Oct 08, 2020

Drugs and Companies using RIOCIGUAT ingredient

NCE-1 date: 08 October, 2017

Market Authorisation Date: 08 October, 2013

Treatment: Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening

Dosage: TABLET

How can I launch a generic of ADEMPAS before it's drug patent expiration?
More Information on Dosage

ADEMPAS family patents

Family Patents

2. Angeliq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6933395 BAYER HLTHCARE PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY
Aug, 2017

(6 years ago)

US8906890 BAYER HLTHCARE Very low-dosed solid oral dosage forms for HRT
Oct, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Mar 01, 2015

Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient

Market Authorisation Date: 29 February, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of ANGELIQ before it's drug patent expiration?
More Information on Dosage

ANGELIQ family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Astepro Allergy patent expiration

ASTEPRO ALLERGY IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 4 months from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(1 year, 4 months from now)

US8071073 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Jun, 2028

(3 years from now)




Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED

How can I launch a generic of ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

ASTEPRO ALLERGY family patents

Family Patents

4. Avelox patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942 BAYER HLTHCARE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

US5849752 BAYER HLTHCARE Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification
Dec, 2016

(7 years ago)

US6610327 BAYER HLTHCARE Pharmaceutical moxifloxacin preparation
Oct, 2019

(4 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-185) Sep 27, 2019

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 December, 1999

Treatment: Method of combating bacteria in a patient

Dosage: TABLET

How can I launch a generic of AVELOX before it's drug patent expiration?
More Information on Dosage

AVELOX family patents

Family Patents

5. Avelox In Sodium Chloride 0.8% In Plastic Container patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942 BAYER HLTHCARE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

US5849752 BAYER HLTHCARE Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification
Dec, 2016

(7 years ago)

US6548079 BAYER HLTHCARE Moxifloxacin formulation containing common salt
Jul, 2020

(3 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-185) Sep 27, 2019

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 30 November, 2001

Treatment: Method of combating bacteria in a patient

Dosage: SOLUTION

How can I launch a generic of AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER family patents

Family Patents

6. Beyaz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE37838 BAYER HLTHCARE Composition for contraception
Jun, 2014

(10 years ago)

USRE43916 BAYER HLTHCARE Composition for contraception
Jun, 2014

(10 years ago)

USRE38253 BAYER HLTHCARE Composition for contraception
Jun, 2014

(10 years ago)

USRE37564 BAYER HLTHCARE Composition for contraception
Jun, 2014

(10 years ago)

US5798338 BAYER HLTHCARE Solid dosage forms that contain clathrates of 17α-ethinyl estradiol
Jul, 2015

(9 years ago)

US6441168 BAYER HLTHCARE Stable crystalline salts of 5-methyltetrahydrofolic acid
Apr, 2020

(4 years ago)

US6958326 BAYER HLTHCARE Cyclodextrin-drospirenone inclusion complexes
Dec, 2021

(2 years ago)

US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Mar, 2022

(2 years ago)

US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(5 years from now)

US11617751 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Jul, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 24, 2013
New Combination(NC) Sep 24, 2013

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 24 September, 2010

Treatment: Method of inducing contraception in a female of reproductive age who has not yet reached premenopause; Prevention of pregnancy; Treatment of mood changes and/or anxiety as symptoms of premenstrual dys...

Dosage: TABLET

How can I launch a generic of BEYAZ before it's drug patent expiration?
More Information on Dosage

BEYAZ family patents

Family Patents

7. Children's Astepro Allergy patent expiration

CHILDREN'S ASTEPRO ALLERGY IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 4 months from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(1 year, 4 months from now)

US8071073 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Jun, 2028

(3 years from now)




Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED

How can I launch a generic of CHILDREN'S ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

CHILDREN'S ASTEPRO ALLERGY family patents

Family Patents

8. Cipro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6136347 BAYER HLTHCARE Flavor-masked pharmaceutical compositions
Jan, 2013

(11 years ago)

US6136347

(Pediatric)

BAYER HLTHCARE Flavor-masked pharmaceutical compositions
Jul, 2013

(11 years ago)

US5695784 BAYER HLTHCARE Flavor-masked pharmaceutical compositions
Dec, 2014

(9 years ago)

US5695784

(Pediatric)

BAYER HLTHCARE Flavor-masked pharmaceutical compositions
Jun, 2015

(9 years ago)




Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 26 September, 1997

Treatment: Use of approved formulations to treat all approved disease indications

Dosage: FOR SUSPENSION

How can I launch a generic of CIPRO before it's drug patent expiration?
More Information on Dosage

CIPRO family patents

Family Patents

9. Cipro Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8187632 BAYER HLTHCARE Sustained-release preparations of quinolone antibiotics
Jun, 2021

(3 years ago)

US7709022 BAYER HLTHCARE Sustained-release preparations of quinolone antibiotics and method for preparation thereof
Jun, 2021

(3 years ago)

US7709022

(Pediatric)

BAYER HLTHCARE Sustained-release preparations of quinolone antibiotics and method for preparation thereof
Dec, 2021

(2 years ago)

US8187632

(Pediatric)

BAYER HLTHCARE Sustained-release preparations of quinolone antibiotics
Dec, 2021

(2 years ago)




Drugs and Companies using CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2002

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

CIPRO XR family patents

Family Patents

10. Climara Pro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5676968 BAYER HLTHCARE Transdermal therapeutic systems with crystallization inhibitors
Oct, 2014

(9 years ago)




Drugs and Companies using ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 21 November, 2003

Treatment: NA

Dosage: FILM, EXTENDED RELEASE

More Information on Dosage

CLIMARA PRO family patents

Family Patents

11. Eovist patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5798092 BAYER HLTHCARE Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production
Aug, 2015

(8 years ago)

US6039931 BAYER HLTHCARE Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
Nov, 2021

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 03, 2013
M(M-155) Mar 27, 2018

Drugs and Companies using GADOXETATE DISODIUM ingredient

NCE-1 date: 03 July, 2012

Market Authorisation Date: 03 July, 2008

Treatment: Magnetic resonance imaging of the liver

Dosage: SOLUTION

More Information on Dosage

EOVIST family patents

Family Patents

12. Gadavist patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5980864 BAYER HLTHCARE 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
Nov, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5980864 BAYER HLTHCARE 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
Nov, 2016

(7 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 14, 2016
New Indication(I-688) Jun 11, 2017
New Indication(I-731) Apr 27, 2019
New Indication(I-801) Jul 12, 2022

Drugs and Companies using GADOBUTROL ingredient

NCE-1 date: 15 March, 2015

Market Authorisation Date: 18 December, 2013

Treatment: Contrast agent for magnetic resonance imaging

Dosage: SOLUTION

More Information on Dosage

GADAVIST family patents

Family Patents

13. Kerendia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(4 years from now)

USRE49826 BAYER HLTHCARE Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
Jul, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-279) Sep 01, 2025
New Chemical Entity Exclusivity(NCE) Jul 09, 2026

Drugs and Companies using FINERENONE ingredient

NCE-1 date: 09 July, 2025

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

KERENDIA family patents

Family Patents

14. Kyleena patent expiration

KYLEENA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7252839 BAYER HLTHCARE Delivery system and a manufacturing process of a delivery system
Nov, 2023

(8 months ago)

US11628088 BAYER HLTHCARE Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection
Feb, 2027

(2 years from now)

US11850182 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10561524 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9615965 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(6 years from now)

US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 16, 2019

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 16 September, 2016

Treatment: A method of preventing pregnancy by providing an intrauterine system (ius), holding an inserter handle with one hand, inserting the ius into the uterus, and moving a slider in the handle to release th...

Dosage: INTRAUTERINE DEVICE

More Information on Dosage

KYLEENA family patents

Family Patents

15. Levitra patent expiration

LEVITRA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696206 BAYER HLTHCARE 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Oct, 2018

(5 years ago)

US6362178 BAYER HLTHCARE 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Oct, 2018

(5 years ago)

US8841446 BAYER HLTHCARE Medicaments containing vardenafil hydrochloride trihydrate
Jul, 2023

(1 year, 12 days ago)

US8273876 BAYER HLTHCARE Medicaments containing vardenafil hydrochloride trihydrate
Jul, 2027

(3 years from now)




Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Market Authorisation Date: 19 August, 2003

Treatment: Erectile dysfunction; Treatment of erectile dysfunction by administering a film-coated tablet

Dosage: TABLET

How can I launch a generic of LEVITRA before it's drug patent expiration?
More Information on Dosage

LEVITRA family patents

Family Patents

16. Menostar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5891868 BAYER HLTHCARE Methods for treating postmenopausal women using ultra-low doses of estrogen
Nov, 2017

(6 years ago)

US6692763 BAYER HLTHCARE Methods for treating postmenopausal women using ultra-low doses of estrogen
Nov, 2017

(6 years ago)




Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 08 June, 2004

Treatment: Prevention of postmenopausal osteoporosis

Dosage: SYSTEM

More Information on Dosage

MENOSTAR family patents

Family Patents

17. Mirena patent expiration

MIRENA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5785053 BAYER HLTHCARE Inserter for the positioning of an intrauterine device
Dec, 2015

(8 years ago)

US11850182 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10561524 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9615965 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(6 years from now)

US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-610) Oct 01, 2012
New Dosing Schedule(D-181) Aug 20, 2023

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 06 December, 2000

Treatment: A method of preventing pregnancy by providing an intrauterine system (ius), holding an inserter handle with one hand, inserting the ius into the uterus, and moving a slider in the handle to release th...

Dosage: INTRAUTERINE DEVICE

More Information on Dosage

MIRENA family patents

Family Patents

18. Natazia patent expiration

NATAZIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6133251 BAYER HLTHCARE Combination compound for contraception based on natural estrogen
Oct, 2016

(7 years ago)

US6884793 BAYER HLTHCARE Combination preparation for contraception based on natural estrogens
Oct, 2016

(7 years ago)

US8071577 BAYER HLTHCARE Multi-phase contraceptive preparation based on a natural estrogen
May, 2026

(1 year, 9 months from now)

US8153616 BAYER HLTHCARE Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
Jan, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 06, 2013
New Indication(I-648) Mar 14, 2015

Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient

Market Authorisation Date: 06 May, 2010

Treatment: Prevention of pregnancy; Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception

Dosage: TABLET

How can I launch a generic of NATAZIA before it's drug patent expiration?
More Information on Dosage

NATAZIA family patents

Family Patents

19. Nexavar patent expiration

NEXAVAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8877933 BAYER HLTHCARE Thermodynamically stable form of a tosylate salt
Dec, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7235576 BAYER HLTHCARE Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jan, 2020

(4 years ago)

US8841330 BAYER HLTHCARE Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jan, 2020

(4 years ago)

US8124630 BAYER HLTHCARE ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jan, 2020

(4 years ago)

US7897623 BAYER HLTHCARE ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
Jan, 2020

(4 years ago)

US7351834 BAYER HLTHCARE ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jan, 2020

(4 years ago)

US8618141 BAYER HLTHCARE Aryl ureas with angiogenesis inhibiting activity
Feb, 2023

(1 year, 5 months ago)

US9737488 BAYER HLTHCARE Pharmaceutical composition for the treatment of cancer
Sep, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Dec 20, 2012
New Indication(I-677) Nov 22, 2016
Orphan Drug Exclusivity(ODE-56) Nov 22, 2020

Drugs and Companies using SORAFENIB TOSYLATE ingredient

Market Authorisation Date: 20 December, 2005

Treatment: Treatment of unresectable hepatocellular carcinoma; Treatment of carcinoma of the thyroid; Treatment of advanced renal cell carcinoma; Treatment of unresectable hepatocellular carcinoma, advanced rena...

Dosage: TABLET

How can I launch a generic of NEXAVAR before it's drug patent expiration?
More Information on Dosage

NEXAVAR family patents

Family Patents

20. Safyral patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5798338 BAYER HLTHCARE Solid dosage forms that contain clathrates of 17α-ethinyl estradiol
Jul, 2015

(9 years ago)

US6441168 BAYER HLTHCARE Stable crystalline salts of 5-methyltetrahydrofolic acid
Apr, 2020

(4 years ago)

US6958326 BAYER HLTHCARE Cyclodextrin-drospirenone inclusion complexes
Dec, 2021

(2 years ago)

US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Mar, 2022

(2 years ago)

US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(5 years from now)

US11617751 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Jul, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 16, 2013

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 16 December, 2010

Treatment: Prevention of pregnancy; Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnan...

Dosage: TABLET

How can I launch a generic of SAFYRAL before it's drug patent expiration?
More Information on Dosage

SAFYRAL family patents

Family Patents

21. Skyla patent expiration

SKYLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5785053 BAYER HLTHCARE Inserter for the positioning of an intrauterine device
Dec, 2015

(8 years ago)

US7252839 BAYER HLTHCARE Delivery system and a manufacturing process of a delivery system
Nov, 2023

(8 months ago)

US11628088 BAYER HLTHCARE Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection
Feb, 2027

(2 years from now)

US11850182 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10561524 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9615965 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(6 years from now)

US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 09, 2016

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 09 January, 2013

Treatment: A method of preventing pregnancy by providing an intrauterine system (ius), holding an inserter handle with one hand, inserting the ius into the uterus, and moving a slider in the handle to release th...

Dosage: INTRAUTERINE DEVICE

More Information on Dosage

SKYLA family patents

Family Patents

22. Staxyn patent expiration

STAXYN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696206 BAYER HLTHCARE 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Oct, 2018

(5 years ago)

US6362178 BAYER HLTHCARE 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Oct, 2018

(5 years ago)

US8613950 BAYER HLTHCARE Pharmaceutical forms with improved pharmacokinetic properties
Dec, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jun 17, 2013

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2010

Treatment: Treatment of erectile dysfunction

Dosage: TABLET, ORALLY DISINTEGRATING

How can I launch a generic of STAXYN before it's drug patent expiration?
More Information on Dosage

STAXYN family patents

Family Patents

23. Stivarga patent expiration

STIVARGA's oppositions filed in EPO
STIVARGA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8637553 BAYER HLTHCARE Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Feb, 2031

(6 years from now)

US9957232 BAYER HLTHCARE 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Jul, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7351834 BAYER HLTHCARE ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jan, 2020

(4 years ago)

US8680124 BAYER HLTHCARE Treatment of cancers with acquired resistance to kit inhibitors
Jun, 2030

(5 years from now)

US9458107 BAYER HLTHCARE Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-667) Feb 25, 2016
New Chemical Entity Exclusivity(NCE) Sep 27, 2017
Orphan Drug Exclusivity(ODE-44) Feb 25, 2020
Orphan Drug Exclusivity(ODE) Feb 25, 2020
New Indication(I-744) Apr 27, 2020
Orphan Drug Exclusivity(ODE-139) Apr 27, 2024

Drugs and Companies using REGORAFENIB ingredient

NCE-1 date: 27 September, 2016

Market Authorisation Date: 27 September, 2012

Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kina...

Dosage: TABLET

How can I launch a generic of STIVARGA before it's drug patent expiration?
More Information on Dosage

STIVARGA family patents

Family Patents

24. Vitrakvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9127013 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(5 years from now)

US8513263 BAYER HLTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(5 years from now)

US10172861 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)

US10799505 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9447104 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(5 years from now)

US8865698 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(5 years from now)

US9676783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(5 years from now)

US10005783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(5 years from now)

US10774085 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(5 years from now)

US10047097 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(5 years from now)

US10813936 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)

US9782414 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)

US10285993 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 26, 2023
Orphan Drug Exclusivity(ODE-221) Nov 26, 2025
Orphan Drug Exclusivity(ODE-215) Nov 26, 2025
Orphan Drug Exclusivity(ODE-220) Nov 26, 2025

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: 26 November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating cancerous solid tumors; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhi...

Dosage: CAPSULE

More Information on Dosage

VITRAKVI family patents

Family Patents

25. Xofigo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635234 BAYER HLTHCARE Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
Jan, 2020

(4 years ago)

US8791127 BAYER HLTHCARE Mucosal bioadhesive slow release carrier for delivering active principles
Mar, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 15, 2018

Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient

NCE-1 date: 15 May, 2017

Market Authorisation Date: 15 May, 2013

Treatment: Therapeutic treatment of bone metastases

Dosage: SOLUTION

More Information on Dosage

XOFIGO family patents

Family Patents

26. Yasmin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5569652 BAYER HLTHCARE Dihydrospirorenone as an antiandrogen
Oct, 2013

(10 years ago)

US6933395 BAYER HLTHCARE PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY
Aug, 2017

(6 years ago)

US6787531 BAYER HLTHCARE Pharmaceutical composition for use as a contraceptive
Aug, 2020

(3 years ago)




Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL ingredient

Market Authorisation Date: 11 May, 2001

Treatment: Prevention of pregnancy

Dosage: TABLET

How can I launch a generic of YASMIN before it's drug patent expiration?
More Information on Dosage

YASMIN family patents

Family Patents

27. Yaz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5569652 BAYER HLTHCARE Dihydrospirorenone as an antiandrogen
Oct, 2013

(10 years ago)

USRE43916 BAYER HLTHCARE Composition for contraception
Jun, 2014

(10 years ago)

USRE38253 BAYER HLTHCARE Composition for contraception
Jun, 2014

(10 years ago)

USRE37838 BAYER HLTHCARE Composition for contraception
Jun, 2014

(10 years ago)

USRE37564 BAYER HLTHCARE Composition for contraception
Jun, 2014

(10 years ago)

US5798338 BAYER HLTHCARE Solid dosage forms that contain clathrates of 17α-ethinyl estradiol
Jul, 2015

(9 years ago)

US6933395 BAYER HLTHCARE PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY
Aug, 2017

(6 years ago)

US6987101 BAYER HLTHCARE Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
Dec, 2017

(6 years ago)

US6787531 BAYER HLTHCARE Pharmaceutical composition for use as a contraceptive
Aug, 2020

(3 years ago)

US6958326 BAYER HLTHCARE Cyclodextrin-drospirenone inclusion complexes
Dec, 2021

(2 years ago)

US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Dec, 2021

(2 years ago)




Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL ingredient

Market Authorisation Date: 16 March, 2006

Treatment: Prevention of pregnancy; Method of inducing contraception in a female of reproductive age who has not yet reached premenopause; Treatment of symptoms of premenstrual dysphoric disorder

Dosage: TABLET

How can I launch a generic of YAZ before it's drug patent expiration?
More Information on Dosage

YAZ family patents

Family Patents